DOCSLIB.ORG

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications Clin Pharmacokinet DOI 10.1007/s40262-016-0407-2 REVIEW ARTICLE Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications 1 2 3 4 E. J. Smolders • C. T. M. M. de Kanter • R. J. de Knegt • M. van der Valk • 5 1 J. P. H. Drenth • D. M. Burger Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Treatment options for chronic hepatitis C virus psychoactive drugs and identify safe options for the (HCV) infection have drastically changed since the simultaneous treatment of mental illnesses and chronic development and licensing of new potent direct-acting HCV infection. antivirals (DAAs). The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes. Additionally, Key Points these DAAs are both substrates and inhibitors of drug transporters, which makes the DAAs both possible victims Escitalopram and citalopram have been studied in or perpetrators of drug–drug interactions (DDIs). There is a combination with most direct-acting antivirals high prevalence of mental illnesses such as depression or (DAAs) and either of these drugs can be safely psychosis in HCV-infected patients; therefore, psychoac- combined with hepatitis C virus (HCV) treatment. tive medications are frequently co-administered with DAAs. The majority of these psychoactive medications are No formal interaction studies between psychoactive also metabolized by CYP enzymes but remarkably little agents and sofosbuvir or ledipasvir have been information is available on DDIs between psychoactive performed in humans. However, these DAAs are medications and DAAs. Hence, the aim of this review is to generally neither victims nor perpetrators of drug provide an overview of the interaction mechanisms interactions and can therefore be safely used in between DAAs and psychoactive agents. In addition, we combination with psychoactive drugs. describe evidenced-based interactions between DAAs and Boceprevir, simeprevir, and the combination paritaprevir/ritonavir plus ombitasvir with dasabuvir are most likely to cause drug interactions via the & D. M. Burger inhibition of cytochrome P450 (CYP) 3A4. [email protected] Therefore, caution must be exercised when CYP3A4 1 Department of Pharmacy, Radboud university medical center, substrates such as midazolam and/or quetiapine are Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The co-administered with these DAAs. Netherlands 2 Department of Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands 3 Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands 1 Introduction 4 Division of Infectious Diseases, Academic Medical Center, Center for Infection and Immunity Amsterdam (CINIMA), Amsterdam, The Netherlands One of the components previously used in the treatment 5 Department of Gastroenterology and Hepatology, Radboud regimen for hepatitis C virus (HCV) is pegylated inter- university medical center, Nijmegen, The Netherlands feron; however, it has major adverse effects on mental E. J. Smolders et al. health and depression was a commonly seen adverse event Little information is available on interactions between [1]. Since the development of novel direct-acting antivirals DAAs and psychoactive agents. Therefore, the aim of this (DAAs), pegylated interferon is no longer used in the review is to provide an overview of the interaction mech- treatment of HCV infections in resource-rich settings. anisms of DAAs and psychoactive agents. In addition, we However, the prevalence of mental disorders remains high describe evidenced-based interactions between DAAs and among untreated HCV-infected patients [2]. For example, a psychoactive drugs and identify safe options for treatment retrospective study reported that 86 % of HCV-infected of the simultaneous treatment of mental illnesses and HCV patients had at least one psychiatric, drug-, or alcohol use- infection. related disorder recorded in their patient charts. The most common conditions were depressive disorders (50 %), psychosis (50 %), anxiety disorders (41 %), post-traumatic 2 Methods stress disorders (34 %), and bipolar disorders (16 %) [3]. Another study reported a prevalence of 41 % for anxiety We searched PubMed (1946–January 2016) and EMBASE and 27 % for depression in HCV-infected individuals (1947–January 2016) to identify peer-reviewed studies. (n = 395) [4]. One explanation for this high prevalence The search covered all DAAs recommended in European was that patients with mental disorders are more likely to and US guidelines [11, 12] and licensed by the European have a drug addiction, because intravenous drug use is a Medicines Agency (EMA) and US Food and Drug major route of HCV transmission [5]. Administration (FDA). The DAAs included protease inhi- The results from a cross-sectional study were in agree- bitors (PIs) (boceprevir, simeprevir, paritaprevir, and gra- ment with the high prevalence of mental disorders. In that zoprevir), NS5A inhibitors (daclatasvir, ledipasvir, study, 16 % of the HCV-infected patients were on antide- ombitasvir, and elbasvir), and NS5B polymerase inhibitors pressants and 10 % were on antipsychotics (n = 3716) [6]. (sofosbuvir and dasabuvir). Telaprevir (PI) was excluded This corresponds with data from a Dutch nationwide sur- from the review because it has limited use in current vey in which benzodiazepines, drugs used for treating therapy. We also referred to the work published by Kiser opioid dependence, and selective serotonin reuptake inhi- and colleagues [13] for more information about telaprevir bitors (SSRIs) were among the drugs most frequently used and DDIs between DAAs and psychoactive drugs. by chronic HCV-infected patients [7]. The psychoactive agents included were SSRIs, TCAs, The use of antipsychotics and antidepressants during typical and atypical antipsychotics, benzodiazepines, DAA therapy increases the risk of drug-drug interactions monoamine oxidase inhibitors, lithium, and St John’s wort. (DDIs). Both DAAs and psychoactive agents are exten- The Google and Google Scholar search engines, and sively metabolized in the liver and have the ability to affect ClinicalTrials.gov (http://www.clinicaltrials.gov) website the activities of various enzymes (e.g., cytochrome P450 and the Liverpool drug interaction database (http://www. [CYP]) and drug transporters (e.g., P-glycoprotein [P-gp]). hep-druginteractions.org) were used to identify conference This makes DAAs as well as psychoactive agents possible papers and abstracts. All searches were performed in victims (objects of DDIs) and perpetrators (causes of DDIs) English. The search items contained generic and/or brand of drug interactions, which could negatively affect treat- names of the drugs and included terms such as antide- ment outcomes as a result of adverse effects (increased pressant, antipsychotic, sedative, and tranquilizer. plasma concentrations) or treatment failure (decreased Information about the pharmacokinetics and metabolism plasma concentrations) [8, 9]. In order to interpret the DDIs of the DAAs and psychoactive agents were obtained from between DAAs and psychoactive agents, it is important to the Summary of Product Characteristics (SmPC) and FDA have sufficient knowledge of their therapeutic ranges. prescribing information for each drug as well as from the Benzodiazepines, tricyclic antidepressants (TCAs), and Lexicomp database (available via http://www.uptodate. antipsychotics have a narrow therapeutic range, while com). Enzyme inhibitors and inducers were defined as SSRIs have a broad therapeutic range. Generally, drugs being strong, moderate, or weak if they changed the area with narrow therapeutic ranges are more likely to have under the plasma concentration–time curve (AUC) of a clinically relevant DDIs than drugs with large therapeutic substrate by 5-fold, [2to\5-fold, and \2-fold, respec- ranges [10]. DAAs have a large therapeutic range, which tively. Substrates were also grouped as being minor and makes them less susceptible to the effects of an increase or major substrates of enzymes. These groupings were based decrease in their plasma concentrations caused by, for on the clinical relevance of the potential interaction example, CYP inhibition or induction. However, extremely described by Lexicomp (http://www.uptodate.com) low plasma concentrations could lead to virologic failure. [14, 15]. DDIs Between DAAs and Psychoactive Medications 3 Drug-Drug Interaction (DDI) Mechanisms: 42 %, respectively. As a result of this, a reduction in the Direct-Acting Antivirals (DAAs) dose of furosemide of up to 50 % might be required if the drugs have to be co-administered [20]. In this section, we elaborate on the mechanisms by which DAAs can be perpetrators and/or victims of DDIs. We 3.2 Phase I and II Reactions: DAAs as Victims focused on interactions through hepatic drug metabolism and drug transporters because they are the most important DAAs, e.g., daclatasvir, simeprevir, grazoprevir, and pathways underlying interactions between DAAs and elbasvir, are predominantly metabolized by CYP3A4/5 in psychoactive agents. These mechanisms are illustrated the liver and gastrointestinal tract. Thus, caution is needed using examples of drug interactions between DAAs and when DAAs are administered with strong inducers or psychoactive agents or non-psychoactive drugs, which inhibitors of CYP3A4. A reduced plasma concentration of were studied in healthy volunteers. DAAs creates a potential
Load more

Recommended publications
  • Product Monograph
    PRODUCT MONOGRAPH PrFLUANXOL® Flupentixol Tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg PrFLUANXOL® DEPOT Flupentixol Decanoate Intramuscular Injection 2% and 10% flupentixol decanoate Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel December 12th, 2017 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 209135 Page 1 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • FDA Approved Drugs with Broad Anti-Coronaviral Activity Inhibit SARS-Cov-2 in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.008482; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro Stuart Weston1, Rob Haupt1, James Logue1, Krystal Matthews1 and Matthew B. Frieman*1 1 - Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore St., Room 380, Baltimore, MD, 21201, USA *Corresponding author. Email: [email protected] Key words: SARS-CoV-2, nCoV-2019, COVID-19, drug repurposing, FDA approved drugs, antiviral therapeutics, pandemic, chloroquine, hydroxychloroquine AbstraCt SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with over 400,000 recorded COVID-19 cases and greater than 19,000 recorded deaths by March 24th, 2020 (www.WHO.org) (1). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2 (2). Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs (3). Rapid development and human testing of potential antivirals is greatly needed. A potentially quicker way to test compounds with antiviral activity is through drug re-purposing (2, 4). Numerous drugs are already approved for use in humans and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to test in COVID-19 patients.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Prescribing for Schizophrenia Guideline
    CLINICAL GUIDELINE: Guidance for: Prescribing Guidance for the Treatment of No: Schizophrenia in Adults Agreed by: The Pharmacological Therapies Committee. January 2016 Trust Clinical Governance Committee. 2016 Aim of guideline The National Institute for Health and Care Excellence (NICE) published a guideline on the Treatment of Schizophrenia in Adults in February 2014. This guideline gives further advice on considerations when prescribing antipsychotics in Schizophrenia, including initial choice, monitoring and follow-up, as well as the approach to treatment-resistant Schizophrenia. Developed by Reaside Pharmacy Manager Consultant Psychiatrist Chief Pharmacist Consultant Psychiatrist Consultant Psychiatrist Consultant Psychiatrist Who it applies to This is prescribing guidance. Process for review / feedback Antipsychotic prescribing within the BSMHFT will be audited in a number of ways via the Pharmacological Therapies Committee for adherence to this guidance. This guidance will be updated annually in the light of any changes to any national or local prescribing practice. The next review date will be January 2018 1 Prescribing Guidance for the Treatment of Schizophrenia in Adults Primary care – make a referral to specialist mental health services Newly diagnosed On going Treatment resistant Should be seen by appropriate service Monitor mental state objectively to assess response to treatment. Offer clozapine if there is an as soon as possible regardless of age inadequate response to the If non-responsive despite increasing dose to maximum dose and Make full assessment and diagnosis sequential use of two different checking for side effects and adherence, then re-assess diagnosis antipsychotics, prescribed at and consider alternative medication Facilitate the choice of medication by adequate doses for a reasonable service user/carer by providing suitable length of time, at least one of Check medication adherence, using plasma assays if necessary.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • The Use of Central Nervous System Active Drugs During Pregnancy
    Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Gianluca BW.Indd
    Use and safety of psychotropic drugs in elderly patients Gianluca Trifi rò GGianlucaianluca BBW.inddW.indd 1 225-May-095-May-09 111:22:461:22:46 AAMM Th e work presented in this thesis was conducted both at the Department of Medical Informatics of the Erasmus Medical Center, Rotterdam, Th e Netherlands and the Depart- ment of Clinical and Experimental Medicine and Pharmacology of University of Messina, Messina, Italy. Th e studies reported in chapter 2.2 and 4.3 were respectively supported by grants from the Italian Drug Agency and Pfi zer. Th e contributions of the general practitioners participating in the IPCI, Health Search/ Th ales, and Arianna databases are greatly acknowledged. Financial support for printing and distribution of this thesis was kindly provided by IPCI, SIMG/Health Search, Eli Lilly Nederland BV, Boehringer-Ingelheim B.V., Novartis Pharma B.V. and University of Messina. Cover design by Emanuela Punzo, Antonio Franco e Gianluca Trifi rò. Th e background photo in the cover is a landscape from Santa Lucia del Mela (Sicily) and was kindly pro- vided by Franco Trifi rò. Th e photo of the elderly person is from Antonio Franco Trifi rò. Layout and print by Optima Grafi sche Communicatie, Rotterdam, Th e Netherlands. GGianlucaianluca BBW.inddW.indd 2 225-May-095-May-09 111:22:481:22:48 AAMM Use and Safety of Psychotropic Drugs in Elderly Patients Gebruik en veiligheid van psychotropische medicaties in de oudere patienten Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • Review Article Monoamine Reuptake Inhibitors in Parkinson's Disease
    Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review
    [Show full text]
  • Concentrations of Antidepressants, Antipsychotics, and Benzodiazepines in Hair Samples from Postmortem Cases
    SN Comprehensive Clinical Medicine (2020) 2:284–300 https://doi.org/10.1007/s42399-020-00235-x MEDICINE Concentrations of Antidepressants, Antipsychotics, and Benzodiazepines in Hair Samples from Postmortem Cases Maximilian Methling1,2 & Franziska Krumbiegel1 & Ayesha Alameri1 & Sven Hartwig1 & Maria K. Parr2 & Michael Tsokos1 Accepted: 30 January 2020 /Published online: 10 February 2020 # The Author(s) 2020 Abstract Certain postmortem case constellations require intensive investigation of the pattern of drug use over a long period before death. Hair analysis of illicit drugs has been investigated intensively over past decades, but there is a lack of comprehensive data on hair concentrations for antidepressants, antipsychotics, and benzodiazepines. This study aimed to obtain data for these substances. A LC-MS/MS method was developed and validated for detection of 52 antidepressants, antipsychotics, benzodiazepines, and metabolites in hair. Hair samples from 442 postmortem cases at the Institute of Legal Medicine of the Charité-University Medicine Berlin were analyzed. Postmortem hair concentrations of 49 analytes were obtained in 420 of the cases. Hair sample segmentation was possible in 258 cases, and the segments were compared to see if the concentrations decreased or increased. Descriptive statistical data are presented for the segmented and non-segmented cases combined (n = 420) and only the segmented cases (n = 258). An overview of published data for the target substances in hair is given. Metabolite/parent drug ratios were investigated for 10 metabolite/parent drug pairs. Cases were identified that had positive findings in hair, blood, urine, and organ tissue. The comprehensive data on postmortem hair concentrations for antidepressants, antipsychotics, and benzodiazepines may help other investigators in their casework.
    [Show full text]
  • Neuroleptics of the Diphenylbutylpiperidine Series Are Potent Calcium Channel Inhibitors
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 7513-7517, October 1986 Neurobiology Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors (fluspirilene/desmethoxverapamil/binding/voltage-clamp/skeletal muscle) JEAN-PIERRE GALIZZI, MICHEL FOSSET, GEORGES ROMEY, PIERRE LADURON*, AND MICHEL LAZDUNSKI Centre de Biochimie du Centre National de la Recherche Scientifique, Parc Valrose, 06034 Nice Cedex, France Communicated by Jean-Marie Lehn, June 5, 1986 ABSTRACT [1t4]Fluspirilene, a neuroleptic molecule of spirilene and directly demonstrate that molecules in the the diphenylbutylpiperidine series, binds to skeletal muscle DPBP series are among the most potent inhibitors of the transverse tubule membranes with a high affinity correspond- skeletal muscle Ca2+ channel. ing to a Kd of 0.11 * 0.04 nM. A 1:1 stoichiometry was found between [3H]fluspirilene binding and the binding of (-)- [3H]desmethoxyverapamil {(-)[3H]D888}, one of the most MATERIALS AND METHODS potent Ca2+ channel inhibitors. Ca2+ channel inhibitors such as D888, verapamil, gallopamil, bepridil, or diltiazem antag- Materials. (-)[3H]D888 (82 Ci/mmol; 1 Ci = 37 GBq) and onize [3H]fluspirilene binding besides antagonizing (-)[3H]- the 1,4-dihydropyridine (+)[3H]PN 200-110 (80 Ci/mmol) D888 binding. Neuroleptics, especially those of the diphenyl- were obtained from Amersham; (-)D888, verapamil, and butylpiperidine family, also antagonize both (-)[3H]D888 gallopamil were from Knoll AG (Ludwigshafen, F.R.G.); binding and [3H]fluspirilene binding. There is an excellent bepridil and the bepridil analogs 4205 {1-[(1-propynyl)- correlation between affinities found from [3H~fluspirilene bind- cyclohexyloxy]-2-(1-pyrrolidinyl)-3-[(2-methyl)propoxyjpro- ing experiments and those found from (-)[3H]D888 binding pane chlorhydrate} and 11787 [N-(4-chloro)phenylmethyl-N- experiments.
    [Show full text]